vorapaxar

01/01/2015 - "The FDA-confirmed evidence strongly suggests that unique pharmacokinetics and a very mild "comfort zone" antiplatelet profile makes vorapaxar a good candidate for improved secondary stroke prevention. "
04/01/2016 - "The effect of vorapaxar on cardiovascular death, MI, or stroke (2.4% vs 4.4%; HR 0.54, 95% CI 0.31 to 0.93; p = 0.027) was consistent with the overall trial result. "
01/01/2016 - "Vorapaxar may be superior to currently recommended antiplatelet strategies and should be tested as a monotherapy in a randomized outcome-driven secondary stroke prevention trial."
01/01/2016 - "Overall, the FDA-confirmed evidence advocates future vorapaxar secondary stroke prevention trial due to being first-in-class agent, unique pharmakynetics, and exhibiting very mild "comfort zone" antiplatelet profile. "
01/01/2016 - "We sought to summarize the conflicting stroke data after vorapaxar for justifying a secondary stroke prevention trial. "

03/01/2017 - "Vorapaxar is effective in the prevention of secondary atherothrombotic events, although the efficacy/safety balance appears less favorable in the treatment of patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS). "
05/15/2011 - "SCH 530348 is a safe and effective oral anti-platelet agent for patients with acute coronary syndrome. "
09/01/2014 - "This study characterized a medically managed population in a non-ST-segment elevation acute coronary syndrome (NSTEACS) cohort and evaluated prognosis and outcomes of vorapaxar vs. placebo. "
01/05/2012 - "In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. "
03/01/2011 - "Two phase 3 trials are evaluating the efficacy and safety of vorapaxar in patients presenting with non-ST-segment elevation acute coronary syndromes and in patients with documented atherothrombotic disease."

06/01/2013 - "In this analysis, we explored the effect of vorapaxar on myocardial infarction (MI). "
10/13/2012 - "17,779 of 26,449 patients had a qualifying myocardial infarction and were assigned treatment (8898 to vorapaxar and 8881 to placebo). "
10/13/2012 - "Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial."
08/01/2016 - "A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction."
04/01/2016 - "Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction."

07/01/2012 - "Recent evidence with vorapaxar has demonstrated an increase in bleeding events with only modest improvement in ischemic outcomes. "
01/01/2020 - "In the TRA-2P-TIMI 50 trial, vorapaxar reduced the risk of primary ischemic outcome but with increased bleeding risk. "
03/01/2017 - "The rate of major bleeding found in patients treated with vorapaxar in randomized trials was consistently higher than placebo in most of the analyzed subgroups. "
03/01/2017 - "In patients undergoing CABG while receiving vorapaxar, bleeding risk appeared similar to that seen in the overall trial population."
12/15/2015 - "GUSTO moderate/severe bleeding was substantially higher with vorapaxar in both trials for the eldest age quintile (5.1% placebo vs. 7.0% vorapaxar in TRA2P; 8.4% placebo vs. 13% vorapaxar in TRACER). "

01/15/2017 - "Compared with placebo, vorapaxar led to a statistically non-significant reduction in risk of MI [RR 0.86; 95% CI 0.80-0.93, p=0.427] and ischemic stroke [RR 0.84; 95% CI 0.72-0.97, p=0.920]. "
01/01/2020 - "The TRA 2°P-TIMI 50 trial randomized 26,449 patients with prior MI, ischemic stroke, or PAD to vorapaxar or placebo. "
12/09/2014 - "New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial."
12/09/2014 - "There does not appear to be a significant increase in the risk of hemorrhagic conversion or death in patients who experienced a first ischemic stroke on vorapaxar. "
12/09/2014 - "Vorapaxar reduces ischemic stroke in patients with MI or PAD and no known CVD. "